Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines

• Published in: Leukemia Vol. 14; no. 5; pp. 841 - 844
• Main Authors: TASSONE, P, FORCINITI, S, GALEA, E, MORRONE, G, TURCO, M. C, MARTINELLI, V, TAGLIAFERRI, P, VENUTA, S
• Format: Conference Proceeding Journal Article
• Language: English
• Published: London Nature Publishing 01.05.2000; Nature Publishing Group
• Subjects: Anticancer properties; Antineoplastic agents; Antitumor activity; Apoptosis; Apoptosis - drug effects; Biological and medical sciences; Biomedical materials; Bisphosphonates; Cell death; Cell Division - drug effects; Cell growth; Clinical medicine; Dexamethasone; Dexamethasone - toxicity; Diphosphonates - toxicity; Drug Synergism; Flow Cytometry - methods; General aspects; Humans; Imidazoles - toxicity; Leukemia; Medical research; Medical sciences; Multiple Myeloma; Myeloma; Osteolysis; Penicillin; Pharmacology. Drug treatments; Steroids; Tumor cell lines; Tumor Cells, Cultured; Zoledronic acid; France; Italy; Antineoplastic agent; Human; Cell proliferation; Immunopathology; Corticosteroid; Dexamethasone; Diphosphonic acid derivatives; Malignant hemopathy; Myeloma; Bisphosphonates; Glucocorticoid; In vitro; Immunoglobulinopathy; Cell death; Lymphoproliferative syndrome; Established cell line; Drug interaction; Inhibition; Apoptosis
• ISSN: 0887-6924; 1476-5551
• DOI: 10.1038/sj.leu.2401770

Bisphosphonates (BPs) are commonly used in the treatment of myeloma-associated osteolytic lesions. Recent reports have suggested that BPs may also exert direct antitumor effects on myeloma cells. Here, we show that the treatment of myeloma cell lines with the combination of the potent BP zoledronate and dexamethasone inhibits cell growth and synergistically induces apoptotic cell death, providing a rationale for potential applications in vivo.